NoAb BioDiscoveries Introduces DTEx (TM) Gene Expression Profiling for Drug Candidates
Published: May 14, 2007
May 14, 2007 Toronto, Canada --NoAb BioDiscoveries announces the availability of DTEx™, a microarray-based technology for profiling the effects of drugs on the gene expression of key proteins involved in drug disposition. As “gatekeepers” for many drug compounds, drug transporters along with metabolic enzymes play a critical role in determining the pharmacodynamic and pharmacokinetic properties of administered drugs. Depending on their levels in different cells, these proteins may alter intestinal uptake, renal excretion, brain penetration, or uptake of drugs into target tissues. DTEx™ examines the drug’s effects on the induction or suppression of these genes in biological systems. This information will help scientists understand potential drug-drug interactions and to select candidates for clinical development with greater efficacy and fewer side effects. NoAb has filed patent applications for the DTEx™ technology.